CAR-T联合疗法治疗实体瘤的研究进展

CAR-T疗法(chimeric antigen receptor T-cell immunotherapy)即嵌合抗原受体T细胞免疫疗法,是目前肿瘤免疫治疗中较有潜力的策略之一^1],已成功应用于多种血液肿瘤的治疗。但CAR-T疗法在治疗实体瘤领域进展缓慢,存在肿瘤微环境的限制、细胞因子释放综合征以及严重的脱靶效应等诸多挑战^2]。与单一靶向治疗相比,CAR-T联合疗法为改进肿瘤治疗方法提供了新的方向。综述目前常用的CAR-T联合治疗策略,针对CAR-T疗法在实体瘤治疗领域面临的主要挑战,探讨提高CAR-T疗效的潜在方案。

Advances in CAR-T Combination Therapy for Solid Tumors

Over the last decade, Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) has become one of the promising strategies in tumor immunotherapy. This technique has been successfully applied in the treatment of various blood tumors. However, CAR-T therapy has made slow progress in the treatment of solid tumors, facing many challenges such as limitation of tumor microenvironment, cytokine release syndrome and severe off-target effect. CAR-T combination therapy offers new directions for improving cancer treatment compared to targeted therapy alone. In this article, we review the major challenges of CAR-T therapy in solid tumors in recent years and the current research progress of commonly used CAR-T combination therapy strategies, in order to explore the potential items for improving the efficacy of CAR-T therapy in the future.